Key takeaways for New Jersey
- • Zepbound is the FIRST and ONLY FDA-approved drug for OSA (Dec 2024).
- • Approved only for moderate-to-severe OSA in adults with obesity.
- • AHI reductions of 25-30 events/hour in the SURMOUNT-OSA trials.
- • NJ FamilyCare coverage rules apply for Obstructive Sleep Apnea patients in New Jersey — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Obstructive Sleep Apnea
Zepbound is FDA-approved (Dec 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. Evidence grade: A. In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index (AHI) by roughly 25-30 events per hour at 52 weeks, with a substantial fraction of patients reaching disease remission. CPAP remains standard of care — Zepbound is positioned as adjunct or alternative for patients who cannot tolerate CPAP. Other GLP-1s (Wegovy, semaglutide) are not approved for OSA but may produce indirect benefit via weight loss.
New Jersey-specific context
New Jersey has telehealth access concentrated in Newark, Jersey City, Paterson metros, with additional reach to Elizabeth and Edison. RWJBarnabas Health, Hackensack Meridian Health, Atlantic Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nj.gov/health.
New Jerseytelehealth & pricing rules
- • New Jersey requires a live video consultation before a GLP-1 prescription.
- • New Jersey allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Jersey: ~$328/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.